BERLIN, Germany // June 2, 2014 .
Bayer has entered into a global agreement with Orion Corporation, a pharmaceutical company based in Espoo, Finland, (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor. ODM-201 is in clinical development for the treatment of patients with prostate cancer. Bayer and Orion plan to start jointly the clinical Phase III program to further evaluate the efficacy and safety of ODM-201 in patients with non-metastatic castration-resistant prostate cancer (nm-CRPC) in 2014. These patients are at high risk of developing metastatic disease and can be identified due to rapid Prostate Specific Antigen (PSA) increases.
...